Skip to content

To study the safety and effectiveness of living plateau equivalent low-altitude buildings on human health in plateau environment

To study the safety and effectiveness of living plateau equivalent low-altitude buildings on human health in plateau environment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089856
Enrollment
Unknown
Registered
2024-09-18
Start date
2023-11-06
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plateau hypoxia

Interventions

Experimental group:Enter equivalent low elevation building

Sponsors

Tibet Autonomous Region People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) age = 18 and < 60 years old; 2)BMI = 28kg/m2; 3) No definite diagnosis of the following diseases: ? cardiovascular diseases such as coronary heart disease, hypertension, hyperlipidemia, cardiomyopathy, valvular disease, congenital heart disease, heart failure, etc; ? Abnormal liver and kidney function; ? hematological diseases; ? endocrine system diseases, such as thyroid disease, gigantism, acromegaly, diabetes, etc.; ? respiratory diseases such as COPD, pulmonary embolism, respiratory failure, etc.; (6) major trauma and physiological deformity; ? Pregnant women; (8) serious diseases of other systems; ? Medication history within 2 weeks (excluding health products); 4) agree to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Participants with any of the following conditions were excluded from the study: 1) resting heart rate 110 BPM; 2) blood pressure = 140/90 mmHg or < 90/60 mmHg; 3) abnormal blood routine, liver and kidney function, electrolyte, blood glucose and blood lipid levels; 4) Significant abnormalities of echocardiography: abnormal cardiac structure, LVEF=50%, abnormal ventricular wall motion, pericardial effusion, pulmonary hypertension, etc. 5) diseases related to contraindications in hyperbaric oxygen chamber; 6) subjects with other diseases or conditions that were assessed by the investigators as not suitable for inclusion in the study; 7) exclude the mental illness of fear of claustrophobia.

Design outcomes

Primary

MeasureTime frame
Blood Oxygen;Blood pressure;Sleep monitoring;

Countries

China

Contacts

Public ContactGesangluobu

People's Hospital of Tibet Autonomous Region Tibet Institute of High-altitude medicine

gesang5354@sina.com+86 135 4901 0066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026